natgillin/translations-raw huggingface dataset:
Aluminium/Aluminium blister with push-through lidding containing 7 modified-release tablets.
Aluminijsko/aluminijski pretisni omot s prekritjem, skozi katerega se potisne tableta; omot vsebuje
It should be used with caution in patients with renal insufficiency, because nicotinic acid and its metabolites are primarily excreted by the kidneys (see sections 4.3, 4.4 and 5.2).
kajti nikotinska kislina in njeni presnovki se izločajo predvsem skozi ledvice (glejte poglavja 4.3, 4.4 in
The mean absolute bioavailability of laropiprant is approximately 71 % following a 40 mg dose when administered as two modified-release tablets of nicotinic acid/laropiprant after an overnight fast.
Povprečna absolutna biološka uporabnost laropipranta po uporabi 40 mg odmerka (v obliki dveh tablet nikotinske kisline/laropipranta s prirejenim sproščanjem na tešče po noči brez hrane) je približno 71 %.
Hepatic insufficiency Pelzont: Use in patients with hepatic insufficiency has not been studied.
Pelzont: Uporaba pri bolnikih z jetrno insuficienco ni raziskana.
• patches of darkened skin
• temne lise na koži
If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Pelzont.
Če niste prepričani, ali kaj od naštetega velja za vas, se, preden vzamete zdravilo Pelzont, posvetujte z zdravnikom ali s farmacevtom.
Drinking alcohol or hot drinks or eating spicy foods can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Pelzont.
V času zaužitja zdravila Pelzont se je treba izogibati pitju alkohola, vročih pijač ali uživanju začinjene hrane, ker to lahko poveča zardevanje.
However, cases of severe hepatic toxicity, including fulminant hepatic necrosis, have occurred in patients who have switched from immediate-release nicotinic acid to long-acting nicotinic acid at equivalent doses.
Vendar pa so se pri bolnikih, ki so z nikotinske kisline s takojšnjim sproščanjem prešli na njeno dolgodelujočo obliko v enakovrednem odmerku, pojavili primeri hudih toksičnih učinkov na jetra
Nicotinic acid: There is no pharmacokinetic data in the elderly (≥ 65 years).
Nikotinska kislina: Farmakokinetičnih podatkov za starejše (≥ 65 let) ni. Glede na sestavljeno analizo preiskovancev, starih od 18 do 65 let, starost na farmakokinetiko nikotinske kisline (pripravka s podaljšanim sproščanjem) ne vpliva klinično pomembno.
• To lower your chance of flushing, avoid drinking alcohol or hot drinks or eating spicy foods near the time you take your dose of Pelzont.
• Da zmanjšate možnost zardevanja, v času zaužitja zdravila Pelzont (ter malo pred tem in po tem) ne pijte alkohola ali vročih pijač in ne jejte začinjene hrane.
Primary means that the hypercholesterolaemia does not have any identifiable cause.
Za primarno hiperholesterolemijo je značilna visoka vrednost holesterola v krvi, primarna pa se imenuje zato, ker niso ugotovili nobenega vzroka za nastanek.
Renal dysfunction
Motnje v delovanju ledvic
LDL cholesterol, fatty substances called triglycerides and apo B (a part of LDL) in the blood;
Ta učinek zdravilo doseže tako, da v krvi zniža raven celotnega holesterola, LDL holesterola, maščobnih snovi, imenovanih trigliceridi, in apo B (ki je del LDL).
This will lower your chance of flushing (redness of the skin, feeling warm, itching, or tingling, particularly in your head, neck, chest and upper back).
občutek toplote, srbenje ali mravljinčenje, še zlasti v predelu glave, vratu, prsi in zgornjega dela hrbta).
In humans, nicotinamide is further predominantly metabolised to N-methylnicotinamide (MNA) and to N-methyl-2-pyridone-5-carboxamide (2PY).
Pri človeku se nikotinamid nato presnovi v glavnem v N-metilnikotinamid (MNA) in
HMG-CoA reductase inhibitors: When simvastatin is combined with nicotinic acid, a modest increase in AUC and Cmax of simvastatin acid (the active form of simvastatin) was observed, which may be devoid of clinical relevance.
in Cmax simvastatinske kisline (aktivne oblike simvastatina) zmerno zvišali, kar je lahko klinično nepomembno.
What Pelzont is and what it is used for
Kaj je zdravilo Pelzont in za kaj ga uporabljamo Vaše zdravilo se imenuje Pelzont.
• stomach ulcer
• želodčna razjeda
Age had no clinically meaningful effect on the pharmacokinetics of laropiprant.
Starost na farmakokinetiko laropipranta ne vpliva klinično pomembno.
Nicotinic acid showed no mutagenic effects in the in vitro assays.
V preizkusih in vitro nikotinska kislina ni učinkovala mutageno.
• sleeplessness
• omedlevica
Rare cases of myopathy/rhabdomyolysis have been associated with concomitant administration of lipid-altering doses (≥ 1,000 mg/day) of nicotinic acid and HMG-CoA reductase inhibitors (statins) (see section 4.8).
ki vplivajo na lipide (≥ 1.000 mg/dan), in zaviralcev reduktaze HMG-CoA (statinov).
14 modified-release tablets 28 modified-release tablets 56 modified-release tablets 168 modified-release tablets 32 x 1 modified-release tablets
14 tablet s prirejenim sproščanjem 28 tablet s prirejenim sproščanjem 56 tablet s prirejenim sproščanjem 84 tablet s prirejenim sproščanjem 98 tablet s prirejenim sproščanjem 168 tablet s prirejenim sproščanjem 196 tablet s prirejenim sproščanjem
Uncommon (may affect up to 1 in 100 people) • gout
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) • glavobol
Laropiprant: Consistent with the characteristics of a medicinal product that is primarily cleared by metabolism, moderate hepatic disease has a significant impact on laropiprant pharmacokinetics, with an increase in AUC and Cmax of approximately 2.8- and 2.2-fold respectively.
Laropiprant: Zmerna bolezen jeter močno vpliva na farmakokinetiko laropipranta, kar je pri zdravilu, ki se očisti predvsem s presnovo, pričakovano.
Talk with your doctor before taking Pelzont if:
Preden vzamete zdravilo Pelzont, se posvetujte z zdravnikom:
This is characterised by multiple symptoms that may include: angio-oedema, pruritus, erythema, paraesthesia, loss of consciousness, vomiting, urticaria, flushing, dyspnoea, nausea, incontinence of urine and stool, cold sweats, shivering, chills, increased blood pressure, lip swelling, burning sensation, drug eruption, arthralgia, leg swelling, and tachycardia.
dispnejo, navzeo, inkontinenco urina in blata, hladno znojenje, drgetanje, mrzlico, zvišan krvni tlak,
Pelzont contains nicotinic acid, which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2 (PGD2) receptor subtype 1 (DP1).
močan, selektiven antagonist receptorja prostaglandina D2 (PGD2) podvrste 1 (DP1).
• dizziness
• drgetanje
Race had no clinically meaningful effect on the pharmacokinetics of laropiprant based on a composite analysis of pharmacokinetic data including subjects of White, Hispanic, Black, Asian, and Native American racial groups.
Glede na sestavljeno analizo farmakokinetičnih podatkov, ki je zajela preiskovance belske, hispanske, črnske, azijske in praameriške rasne skupine, rasa na farmakokinetiko laropipranta ne vpliva klinično pomembno.
How to store Pelzont
Shranjevanje zdravila Pelzont
• generalised swelling
• generalizirano otekanje
Race has no clinically meaningful effect on the pharmacokinetics of nicotinic acid (prolonged-release formulation) based on pharmacokinetic data including subjects of Hispanic, White, Black, and Native American racial groups.
Glede na farmakokinetične podatke preiskovancev, med katerimi so bili pripadniki hispanske, belske, črnske in praameriške rasne skupine, rasa na farmakokinetiko nikotinske kisline (pripravka s podaljšanim sproščanjem) ne vpliva klinično pomembno.
98 modified-release tablets
98 tablet s prirejenim sproščanjem.
Laropiprant was not teratogenic in rats or in rabbits at systemic exposure levels at least 153 and 438 times the human exposure based on the AUC of the recommended daily human dose.
Laropiprant pri podganah oz. kuncih ni bil teratogen pri sistemski izpostavljenosti, ki je bila vsaj 153- oz.
BATCH NUMBER Lot
Ukinitev laropipranta
Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Pelzont be administered > 1 hour before or > 4 hours after administration of a bile acid sequestrant (see section 4.5).
Zato je zdravilo Pelzont priporočljivo zaužiti več kot 1 uro pred izmenjevalci žolčnih kislin ali več kot 4 ure po njih (glejte poglavje 4.5).
• tingling or numbness of the hands or feet
• mravljinčenje in omrtvelost dlani ali stopal • bolečine v trebuhu
Common (may affect up to 1 in 10 people)
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov)
Patients switching from less than 2,000 mg of prolonged-release nicotinic acid should initiate therapy at the starting dose of 1,000 mg/20 mg and advance to the 2,000 mg/40 mg maintenance dose after four weeks.
Pelzont začeti z odmerkom 1.000 mg/20 mg in po 4 tednih preiti na vzdrževalni odmerek 2.000 mg/40 mg.
Pharmacotherapeutic group: Lipid modifying agents, nicotinic acid and derivatives, ATC code: C10AD52.
Oznaka ATC: C10AD52.
• fainting
• spahovanje
Therefore, Pelzont should be used with caution in patients with or predisposed to gout.
Zato morate pri bolnikih, nagnjenih k protinu, zdravilo Pelzont previdno uporabljati.
• nausea (feeling sick)
• siljenje na bruhanje (slabost v želodcu)
If you are not sure, talk to your doctor or pharmacist before taking Pelzont.
Če ste negotovi, se posvetujte s svojim zdravnikom ali s farmacevtom.
Modified-release tablet.
7 tablet s prirejenim sproščanjem.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each modified-release tablet contains 1,000 mg of nicotinic acid and 20 mg of laropiprant.
Ena tableta s prirejenim sproščanjem vsebuje 1.000 mg nikotinske kisline in 20 mg laropipranta.
Aluminium/Aluminium blister with push-through lidding in pack sizes of 14, 28, 56, 168 modified-release tablets and 32 x 1 modified-release tablets in perforated unit dose blister.
Velikosti pakiranj: 14, 28, 56, 168 tablet s prirejenim sproščanjem ter 32 x 1 tableta s prirejenim sproščanjem v perforiranem pretisnem omotu za enkratni odmerek..
• You are breast-feeding or plan to breast-feed.
• če dojite ali nameravate dojiti.
• shivering
• tesnoba
Cases of overdose have been reported; the maximum dose of Pelzont taken was 5,000 mg/100 mg. All patients recovered without sequelae.
Poročali so o primerih prevelikega odmerjanja; največji zaužiti odmerek zdravila Pelzont je bil
84 modified-release tablets
49 x 1 tableta s prirejenim sproščanjem
Check with your doctor or pharmacist before and while taking your medicine if:
Preden vzamete in če že jemljete zdravilo, se posvetujte z zdravnikom ali s farmacevtom:
• you have thyroid problems.
• če imate težave s ščitnico.
Not known: jaundice
Občasni: mialgija
In rats, foetotoxic effects (significantly decreased foetal body weights associated with a decrease in the number of ossified sacrocaudal vertebrae and an increased incidence of foetuses with sites of incomplete ossification) were noted in the absence of any signs of maternal toxicity at exposure levels approximately 959 times the human AUC of nicotinic acid at the recommended daily human dose.
Pri podganah so pri izpostavljenostih, ki so bile približno 959-kratnik vrednosti AUC nikotinske kisline pri človeku pri priporočenem dnevnem odmerku, opazili škodljive učinke na plod
Common: headache; paraesthesia Uncommon: dizziness Rare: migraine; syncope
Pogosti: občutek vročine Občasni: mrzlica; bolečina; periferni edem
• pain
• putika
Posology
Zardevanje
Pelzont in terms of number of days per week with moderate or greater flushing, p< 0.001, Figure 2.
20 tednih zdravljenja z zdravilom Pelzont prenehali jemati laropiprant, bistveno več zardevanja kot pri bolnikih, ki so nadaljevali z jemanjem zdravila Pelzont, kar je bilo izraženo s številom dni v tednu z zmernim ali izrazitejšim zardevanjem, p < 0,001, Slika 2.
28 modified-release tablets
14 tablet s prirejenim sproščanjem28 tablet s prirejenim sproščanjem
The European Commission granted a marketing authorisation valid throughout the European Union for Actraphane on 7 October 2002.
Evropska komisija je dovoljenje za promet z zdravilom Actraphane, veljavno po vsej Evropski uniji, odobrila 7. oktobra 2002.
The full EPAR for Actraphane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Actraphane je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
What measures are being taken to ensure the safe and effective use of Actraphane?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Actraphane?
Actraphane is given 30 minutes before a meal.
Zdravilo Actraphane se daje 30 minut pred obrokom.
This is a summary of the European public assessment report (EPAR) for Actraphane.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Actraphane.
For more information about treatment with Actraphane, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Actraphane preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Actraphane is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Actraphane je bil pripravljen načrt obvladovanja tveganj.
Other information about Actraphane
Druge informacije o zdravilu Actraphane
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Actraphane, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Actraphane in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Actraphane contains insulin in two forms: a soluble form, which acts quickly (within 30 minutes of injection) and an isophane form, which is absorbed much more slowly during the day.
Zdravilo Actraphane vsebuje insulin v dveh oblikah: v topni obliki, ki začne učinkovati hitro (v 30 minutah po injiciranju), ter v obliki izofan, ki se čez dan absorbira veliko počasneje.
The most common side effect with Actraphane (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Najpogostejši neželeni učinek zdravila Actraphane (opažen pri več kot 1 bolniku od 10) je hipoglikemija (nizka raven glukoze v krvi).
The CHMP decided that Actraphane's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Actraphane večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What benefit has Actraphane shown during the studies?
Kakšne koristi je zdravilo Actraphane izkazalo med študijami?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Actraphane.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Actraphane, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Actraphane has been studied in a total of 294 patients with type 1 diabetes, when the pancreas cannot produce insulin, and type 2 diabetes, when the body is unable to use insulin effectively.
Zdravilo Actraphane so preučili pri skupno 294 bolnikih s sladkorno boleznijo tipa 1, pri kateri trebušna slinavka ne more tvoriti insulina, in s sladkorno boleznijo tipa 2, pri kateri telo ne more učinkovito izrabiti insulina.
The active substance in Actraphane, human insulin, is produced by a method known as ‘recombinant technology': the insulin is made by yeast cells into which a gene (DNA) has been introduced, which makes them able to produce insulin.
Zdravilna učinkovina v zdravilu Actraphane, humani insulin, se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri se v celice kvasovk vstavi gen (DNK), ki jim daje sposobnost tvorjenja insulina.
What is the risk associated with Actraphane?
Kakšna tveganja so povezana z zdravilom Actraphane?
Actraphane was effective for both type 1 and type 2 diabetes.
Zdravilo Actraphane se je izkazalo kot učinkovito tako pri sladkorni bolezni tipa 1 kot tudi tipa 2.
It is available as vials, cartridges (Penfill) or prefilled pens (InnoLet or FlexPen).
Na voljo je v vialah, injekcijskih vložkih (Penfill) ali napolnjenih injekcijskih peresnikih (InnoLet ali FlexPen).
Actraphane is a suspension for injection that contains the active substance human insulin.
Zdravilo Actraphane je suspenzija za injiciranje, ki vsebuje zdravilno učinkovino humani insulin.
Actraphane led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with other human insulin.
Zdravilo Actraphane je privedlo do znižanja ravni HbA1c, kar kaže, da so bile ravni glukoze v krvi uravnane na podobno raven kot pri drugih humanih insulinih.
The study compared Actraphane 30 to a similar mix, but made up using an insulin analogue (insulin aspart).
V študiji so zdravilo Actraphane 30 primerjali s podobno mešanico, ki pa je vsebovala analog insulina (insulin aspart).
Actraphane is used to treat diabetes.
Zdravilo Actraphane se uporablja za zdravljenje sladkorne bolezni.
Actraphane is given by injection under the skin in the thigh, the abdominal wall (at the front of the waist), the gluteal region (buttocks) or the deltoid region (shoulder).
Zdravilo Actraphane se injicira v podkožje stegna, trebušne stene (sprednjega dela trebuha), glutealnega predela (zadnjice) ali deltoidnega predela (ramena).
Actraphane is a replacement insulin which is very similar to the insulin made by the pancreas.
Zdravilo Actraphane je nadomestni insulin, ki je zelo podoben insulinu, ki ga proizvaja trebušna slinavka.
Why has Actraphane been approved?
Zakaj je bilo zdravilo Actraphane odobreno?
How has Actraphane been studied?
Kako je bilo zdravilo Actraphane raziskano?
What is Actraphane used for?
Za kaj se zdravilo Actraphane uporablja?
Actraphane contains both fast-acting (soluble) and long-acting (isophane) insulin:
Zdravilo Actraphane vsebuje tako hitrodelujoči (topni) kot tudi dolgodelujoči (izofan) insulin.
How is Actraphane used?
Kako se zdravilo Actraphane uporablja?
What is Actraphane?
Kaj je zdravilo Actraphane?
This gives Actraphane a longer duration of action.
To podaljša čas delovanja zdravila Actraphane.
How does Actraphane work?
Kako zdravilo Actraphane deluje?
Shake well and use immediately.
Dobro pretresite in uporabite takoj.
Provide enough space so that all pigs can drink the required amount.
Omogočite dovolj prostora, da bodo lahko vsi prašiči zaužili potrebno količino.
ATCvet code: QI09AE03.
Oznaka ATC vet: QI09AE03.
The actual amount of water consumed may however vary considerably depending on several factors.
Dejanska količina popite vode je lahko zelo različna, kar je odvisno od več dejavnikov.
The active substance being a principle of biological origin intended to produce a state of immunity is not within the scope of Regulation (EC) No 470/2009.
Učinkovina, ki je v osnovi biološkega izvora namenjena vzbujanju aktivne imunosti, ne spada v področje uporabe Uredbe (ES) št. 470/2009.
Each dose of vaccine contains:
En odmerek cepiva vsebuje:
Withhold drinking water supply for 1 to 2 hours prior to the planned vaccination to stimulate drinking of the vaccine suspension.
Dovajanje pitne vode prekinite od 1 do 2 uri pred načrtovanim cepljenjem, da spodbudite pitje suspenzije cepiva.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
SPC so bodisi dovoljenje snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben ali pa ne spadajo v področje uporabe Uredbe (ES) št. 470/2009, kadar so uporabljene tako kot v tem zdravilu za uporabo v veterinarski medicini.
Duration of immunity: 21 days after vaccination.
Trajanje imunosti: 21 dni po cepljenju.
The suspension should be administered within 4 hours after preparation.
Suspenzijo je treba uporabiti v 4 urah po pripravi.
Cardboard box
kartonasta škatla
Vials (50 or 200 doses)
viale (50 ali 200 odmerkov)
Poligono La Relva, Torneiros s/n 36410 Porriño (Pontevedra) SPAIN
Poligono La Relva, Torneiros s/n 36410 Porriño (Pontevedra) ŠPANIJA
The drinking water systems have to be cleaned and intensively rinsed with untreated water to avoid any residues of antimicrobials, detergents or disinfectants.
Vodne sisteme za pitje je treba očistiti in temeljito sprati s čisto vodo, da se izognete kakršnim koli ostankom antibiotikov, detergentov ali dezinfekcijskih sredstev.
All materials used in preparing and administering the vaccine must be free of antimicrobials, detergent or disinfectant residues to prevent inactivation.
Vsi materiali, ki se uporabljajo pri pripravi in uporabi cepiva, morajo biti brez ostankov antibiotikov, detergentov ali dezinfekcijskih sredstev, da preprečite inaktivacijo.
Manufacturer responsible for batch release: CZ Veterinaria S.A.
Proizvajalec odgovoren za sproščanje serij: CZ Veterinaria S.A.
Date of first authorisation:16/03/2015 Date of latest renewal: dd/mm/yyyy
Datum pridobitve dovoljenja za promet: 16/03/2015 Datum zadnjega podaljšanja dovoljenja za promet: 07/11/2019
Vaccination by drench application:
Cepljenje z drenažno aplikacijo:
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/)
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/).
The final concentration of the skimmed milk powder should be 5 g/litre.
Končna koncentracija posnetega mleka v prahu mora biti 5 g/liter.
As an example, for a 4-hour consumption of 22 l and a dosing pump rate of 1%, the volume of the stock solution should be 22 l x 0.01 = 220 ml.
Na primer pri 4-urni porabi 22 l in hitrosti črpalke 1 % bo volumen osnovne raztopine 22 l x 0,01 = 220 ml.
Onset of immunity: 7 days after vaccination.
Začetek imunosti: 7 dni po cepljenju.
Pregnancy and lactation: The use is not recommended during pregnancy.
Brejost in laktacija: Uporaba med brejostjo ni priporočljiva.
80689 München GERMANY
80689 München
Type I glass vial of 6 ml containing 50 doses and of 11 ml containing 200 doses with a chlorobutyl rubber stopper sealed with an aluminum cap.
Viala (steklo tipa I) s 6 ml, ki vsebuje 50 odmerkov, in 11 ml, ki vsebuje 200 odmerkov, z zamaškom iz klorobutilne gume, zatesnjenim z aluminijasto zaporko.
In case of concerns about the presence of disinfectant residues in the drinking water, it is recommended to add skimmed milk powder as a stabilizer into the drinking water prior to adding the vaccine.
Če sumite, da so v vodi za pitje ostanki dezinfekcijskih sredstev, je priporočljivo, da vodi za pitje pred dodajanjem cepiva kot stabilizator dodate posneto mleko v prahu.
The final concentration of the skimmed milk powder should be 5 g/l.
Končna koncentracija posnetega mleka v prahu mora biti 5 g/l.
50 doses 4 x 50 doses 200 doses
50 odmerkov 4 x 50 odmerkov 200 odmerkov
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal.
Ni podatkov o varnosti ter učinkovitosti ob uporabi tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini.
Shelf life of the veterinary medicinal product as packaged for sale : 18 months.
Rok uporabnosti zdravila v pakiranju za prodajo: 18 mesecev.